Canaan VII

OncoResponse Inc. is an immuno-oncology company based in Houston, Texas, focused on discovering new cancer immunotherapies and therapeutic antibodies. The company collaborates with MD Anderson Cancer Center to utilize the I-STAR™ platform, which analyzes the human memory B-cell repertoire of patients who have demonstrated exceptional responses to immunotherapy, referred to as "Elite Responders." By studying these patients, OncoResponse aims to harness the human immune system to identify fully human monoclonal antibodies and novel targets. This approach is intended to facilitate the development of innovative antibody-derived therapeutics for cancer treatment.

Creating novel bispecific antibodies that activate the immune system to fight cancer

Mantra Health is a developer of a mental healthcare platform specifically designed to cater to students. The platform provides access to psychiatric care, free online assessments, and scheduled initial video consultations, allowing students to receive personalized care plans. By facilitating treatment in a comfortable and accessible manner, Mantra Health aims to enhance the mental well-being of students, making it easier for them to seek help and manage their mental health from the convenience of their homes.

Antiva Biosciences is a biopharmaceutical company developing novel, localized therapeutics for the treatment of diseases caused by HPV infection. The company was founded as Hera Therapeutics in 2012 by Dr. Karl Hostetler at The University of California San Diego. They are now Antiva Biosciences which is headquartered in South San Francisco.

Mantra Health is a developer of a mental healthcare platform specifically designed to cater to students. The platform provides access to psychiatric care, free online assessments, and scheduled initial video consultations, allowing students to receive personalized care plans. By facilitating treatment in a comfortable and accessible manner, Mantra Health aims to enhance the mental well-being of students, making it easier for them to seek help and manage their mental health from the convenience of their homes.

OncoResponse Inc. is an immuno-oncology company based in Houston, Texas, focused on discovering new cancer immunotherapies and therapeutic antibodies. The company collaborates with MD Anderson Cancer Center to utilize the I-STAR™ platform, which analyzes the human memory B-cell repertoire of patients who have demonstrated exceptional responses to immunotherapy, referred to as "Elite Responders." By studying these patients, OncoResponse aims to harness the human immune system to identify fully human monoclonal antibodies and novel targets. This approach is intended to facilitate the development of innovative antibody-derived therapeutics for cancer treatment.

Tyra Biosciences is a clinical-stage biotechnology company based in Carlsbad, California, focused on developing small molecule therapies for cancer treatment. Founded in 2018, the company aims to address drug resistance in oncology by targeting specific pathways associated with acquired resistance. Tyra Biosciences employs its proprietary precision medicine platform, SNÅP, to facilitate rapid drug design through molecular snapshots, enabling the prediction of genetic alterations that may lead to resistance against existing therapies. The company's lead product candidate, TYRA 300, is an FGFR3 selective inhibitor, primarily aimed at treating patients with metastatic urothelial carcinoma of the bladder and urinary tract. Through innovative approaches, Tyra Biosciences seeks to create next-generation precision medicines that significantly improve treatment outcomes for cancer patients.

Day One Biopharmaceuticals is a clinical-stage biotechnology company focused on developing targeted therapies for genetically defined cancers in patients of all ages, with an initial emphasis on pediatric patients. Founded in 2018 and headquartered in South San Francisco, California, the company aims to address the critical needs of children and adults diagnosed with cancer by creating innovative treatments derived from the biology of childhood cancer. Day One Biopharmaceuticals prioritizes programs that can be swiftly brought to market, thereby providing timely options for families facing cancer diagnoses. Its lead product candidate, DAY101, is an oral, brain-penetrant pan-RAF kinase inhibitor designed to target specific cancer types. The company seeks to license and acquire promising therapeutic products from research institutions and other biotechnology and pharmaceutical companies, striving to enhance the treatment landscape for underserved populations.

Synova Life Sciences is developing a novel non-enzymatic device to obtain stem cells from adipose tissue for medical research and therapy. They help physicians and patients harvest autologous stem cells and use their regenerative ability to enhance the quality of life. Synova Life Sciences is the winner of Cal State Fullerton Business Plan Competition 2013, MD&M West "Shark Tank" 2015, TriTech Funding the Big Idea 2015 and was the First Runner Up at TCVN Survivor 8. Synova Life Sciences was founded in 2013.

Vivace Therapeutics, Inc. is a small molecule discovery and development company focused on creating innovative cancer therapeutics by targeting the Hippo pathway, which plays a critical role in tissue regeneration and organ development. Founded in 2014, the company is based in San Mateo, California, and operates with a commitment to advancing novel therapies that can improve outcomes for cancer patients. Vivace Therapeutics emphasizes a capital-efficient and modality-indifferent approach, collaborating with leading academic laboratories to leverage cutting-edge research. Its experienced management team and top-tier scientists aim to develop treatments that can be used independently or in combination with existing therapies, ultimately striving to enhance the lives of individuals affected by cancer.

Stargazer Pharmaceuticals Inc. is a biopharmaceutical company based in Boston, Massachusetts, founded in 2018. The company specializes in developing and manufacturing therapies for rare eye diseases, with a particular focus on Stargardt’s disease, a form of juvenile retinal degeneration. Currently operating in stealth mode, Stargazer Pharmaceuticals aims to provide novel treatment options for conditions that lack existing therapies, thus enabling healthcare professionals to better address the needs of patients with these rare diseases.

Relievant Medsystems, Inc. is a medical device company focused on addressing chronic axial low back pain through a minimally invasive procedure known as Intracept. This innovative treatment specifically targets the basivertebral nerve, utilizing radio-frequency energy delivered through a small access tube into the vertebral body to ablate the nerve. The procedure is performed under real-time fluoroscopic guidance, ensuring precision and safety. Founded in 2004 and headquartered in Minneapolis, Minnesota, with an additional office in Sunnyvale, California, Relievant aims to provide low-risk therapeutic solutions that significantly improve the quality of life for patients suffering from vertebrogenic low back pain.

Vineti is a commercial cloud-based platform that expands patient access to life-saving cells and gene therapies. The software solution offers an independent, purpose-built enterprise solution that is essential for enabling the growth and wide distribution of transformative personalized therapeutics, such as CAR-T cell therapies, for the treatment of late-stage cancer. The Vineti Personalized Therapy Management (PTM) ® platform automates patient-centric supply chains for a wide range of advanced therapies, in all phases of clinical development and commercial operations. Veneti aims to solve the key challenges patients, medical providers, pharmaceutical companies, and regulators face in the delivery and commercialization of personalized medicine. Amy DuRoss, Heidi M. Hagen, Malek Faham, Razmik Abnous, and Stephen Ting co-founded Vineti in San Francisco, California in 2016.

Synthekine Inc. is a biotechnology company focused on the development of engineered cytokine therapies and immunotherapies aimed at treating cancer and autoimmune disorders. Founded in 2018 and based in Menlo Park, California, Synthekine utilizes innovative platform technologies, including engineered partial agonists and orthogonal cell therapies, to create differentiated therapeutics. Its product pipeline features STK-009, an orthogonal ligand, and SYNCAR-001, a CAR-T therapy modified with orthogonal receptors. Additionally, the company is advancing STK-012, a partial agonist of IL-2, alongside Synthekines, which are designed to enhance signaling activities by combining cytokine receptors without relying on wild-type cytokines. Synthekine's approach is informed by immunological insights to ensure that its treatments are both safe and effective, with promising preclinical results indicating potential for improved efficacy and tolerability.

Day One Biopharmaceuticals is a clinical-stage biotechnology company focused on developing targeted therapies for genetically defined cancers in patients of all ages, with an initial emphasis on pediatric patients. Founded in 2018 and headquartered in South San Francisco, California, the company aims to address the critical needs of children and adults diagnosed with cancer by creating innovative treatments derived from the biology of childhood cancer. Day One Biopharmaceuticals prioritizes programs that can be swiftly brought to market, thereby providing timely options for families facing cancer diagnoses. Its lead product candidate, DAY101, is an oral, brain-penetrant pan-RAF kinase inhibitor designed to target specific cancer types. The company seeks to license and acquire promising therapeutic products from research institutions and other biotechnology and pharmaceutical companies, striving to enhance the treatment landscape for underserved populations.

Vineti is a commercial cloud-based platform that expands patient access to life-saving cells and gene therapies. The software solution offers an independent, purpose-built enterprise solution that is essential for enabling the growth and wide distribution of transformative personalized therapeutics, such as CAR-T cell therapies, for the treatment of late-stage cancer. The Vineti Personalized Therapy Management (PTM) ® platform automates patient-centric supply chains for a wide range of advanced therapies, in all phases of clinical development and commercial operations. Veneti aims to solve the key challenges patients, medical providers, pharmaceutical companies, and regulators face in the delivery and commercialization of personalized medicine. Amy DuRoss, Heidi M. Hagen, Malek Faham, Razmik Abnous, and Stephen Ting co-founded Vineti in San Francisco, California in 2016.

Tyra Biosciences is a clinical-stage biotechnology company based in Carlsbad, California, focused on developing small molecule therapies for cancer treatment. Founded in 2018, the company aims to address drug resistance in oncology by targeting specific pathways associated with acquired resistance. Tyra Biosciences employs its proprietary precision medicine platform, SNÅP, to facilitate rapid drug design through molecular snapshots, enabling the prediction of genetic alterations that may lead to resistance against existing therapies. The company's lead product candidate, TYRA 300, is an FGFR3 selective inhibitor, primarily aimed at treating patients with metastatic urothelial carcinoma of the bladder and urinary tract. Through innovative approaches, Tyra Biosciences seeks to create next-generation precision medicines that significantly improve treatment outcomes for cancer patients.

Grey Wolf Therapeutics is a biotechnology company based in Oxford, United Kingdom, focused on developing innovative immunotherapies for oncology. Founded in 2017, the company aims to enhance the visibility of non-responsive tumors to the immune system by directly modifying tumor cells. Its approach involves targeting endoplasmic reticulum aminopeptidases (ERAP) 1 and 2 within the antigen presentation pathway, which increases the neoantigen repertoire on tumor cells. This strategy is designed to improve the effectiveness of immunotherapy in treating cancer. Grey Wolf collaborates with leading academic and commercial partners to advance its drug discovery initiatives and deliver clinical candidates against well-validated targets in the field of immuno-oncology.

Pathios Therapeutics Limited is an early-stage drug discovery company based in Oxford, United Kingdom, that specializes in developing therapies for autoimmune diseases and cancer. Founded in 2017, the company is dedicated to creating innovative treatments to address significant unmet medical needs in these areas.

Intrepida Bio, Inc., a biotechnology company, develops cancer drugs that alter the body’s first line of defense, and innate immunity. It also discovers and develops medicines that modulate the innate immune system to fight cancer and other diseases; and develops monoclonal antibodies that block the novel targets BAG3 and its receptor IFITM-2 to thwart their ability to create a favorable environment for tumor growth. Intrepida Bio, Inc. was incorporated in 2016 and is headquartered in San Diego, California.

Qlaris Bio, Inc., a biotechnology company, develops therapies for debilitating ophthalmic diseases. It offers QLS-101, a therapy to reduce intraocular pressure. Qlaris Bio, Inc. was founded in 2017 and is headquartered in Wellesley, Massachusetts.

Comet Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2018. It specializes in developing novel small-molecule treatments targeting various diseases, particularly orphan neurological disorders. The company's core innovation is its CoEnzyme metabolism platform, which aims to restore dysregulated CoEnzyme A metabolism. This therapeutic approach enables healthcare providers to address significant unmet medical needs in the treatment of these complex conditions.

Kin Euphorics is a New York-based company, founded in 2017, that specializes in non-alcoholic beverages designed to enhance social experiences. The company's offerings include ready-to-drink tonics made from a combination of nootropics, adaptogens, and botanicals. These functional beverages aim to promote a sense of focused relaxation, helping consumers unwind without inducing sleepiness or compromising cognitive function. Kin Euphorics targets individuals seeking a balanced and nourishing alternative to traditional alcoholic drinks, allowing them to enjoy social interactions while supporting their mental well-being.

Nocion Therapeutics, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, established in 2017. The company focuses on developing novel therapeutics called "nocions," which are designed to treat conditions associated with neurogenic inflammation. These nocions specifically target activated sensory neurons, entering nociceptors through large-pore channels that open in response to stimulation. This mechanism allows for the selective blocking of sodium channels, providing targeted and sustained relief for serious conditions such as cough, itch, pain, and inflammation. By offering an alternative to traditional small molecule anesthetics, Nocion Therapeutics aims to deliver more effective treatment options for patients suffering from these debilitating symptoms.

Hyalex Orthopaedics, Inc. is a medical device company based in Lexington, Massachusetts, focused on developing innovative products that utilize HYALEX technology, a synthetic polymer engineered to mimic cartilage. Founded in 2016, the company specializes in creating a biomimetic material that can effectively simulate healthy cartilage to treat diseased or damaged joints. The unique properties of HYALEX allow it to maintain low friction and wear, even under the significant loads typically experienced in human joints. This capability enables surgeons to replace arthritic cartilage while preserving healthy bone. Although Hyalex Orthopaedics is advancing its product development, its offerings have not yet received approval for use in humans from any regulatory agency.

Grey Wolf Therapeutics is a biotechnology company based in Oxford, United Kingdom, focused on developing innovative immunotherapies for oncology. Founded in 2017, the company aims to enhance the visibility of non-responsive tumors to the immune system by directly modifying tumor cells. Its approach involves targeting endoplasmic reticulum aminopeptidases (ERAP) 1 and 2 within the antigen presentation pathway, which increases the neoantigen repertoire on tumor cells. This strategy is designed to improve the effectiveness of immunotherapy in treating cancer. Grey Wolf collaborates with leading academic and commercial partners to advance its drug discovery initiatives and deliver clinical candidates against well-validated targets in the field of immuno-oncology.

Halda Therapeutics is a research-stage drug discovery company, seeking to create the next generation of precision medicine based on a novel therapeutic modality which may be a platform for a number of disease states.

OncoResponse Inc. is an immuno-oncology company based in Houston, Texas, focused on discovering new cancer immunotherapies and therapeutic antibodies. The company collaborates with MD Anderson Cancer Center to utilize the I-STAR™ platform, which analyzes the human memory B-cell repertoire of patients who have demonstrated exceptional responses to immunotherapy, referred to as "Elite Responders." By studying these patients, OncoResponse aims to harness the human immune system to identify fully human monoclonal antibodies and novel targets. This approach is intended to facilitate the development of innovative antibody-derived therapeutics for cancer treatment.

Antiva Biosciences is a biopharmaceutical company developing novel, localized therapeutics for the treatment of diseases caused by HPV infection. The company was founded as Hera Therapeutics in 2012 by Dr. Karl Hostetler at The University of California San Diego. They are now Antiva Biosciences which is headquartered in South San Francisco.

Relievant Medsystems, Inc. is a medical device company focused on addressing chronic axial low back pain through a minimally invasive procedure known as Intracept. This innovative treatment specifically targets the basivertebral nerve, utilizing radio-frequency energy delivered through a small access tube into the vertebral body to ablate the nerve. The procedure is performed under real-time fluoroscopic guidance, ensuring precision and safety. Founded in 2004 and headquartered in Minneapolis, Minnesota, with an additional office in Sunnyvale, California, Relievant aims to provide low-risk therapeutic solutions that significantly improve the quality of life for patients suffering from vertebrogenic low back pain.

EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company is known for its Transoral Incisionless Fundoplication (TIF®) procedure, which provides a minimally invasive alternative to traditional surgical methods by allowing treatment without external incisions. Key products include the EsophyX technology, which facilitates transoral reconstructive surgery, and the SerosaFuse Fasteners, designed for secure tissue attachment. Additionally, EndoGastric Solutions offers training courses for surgeons and a range of consultative support services. Founded in 2002 and headquartered in Redmond, Washington, the company also has an office in San Mateo, California.

PACT Pharma, Inc. is engaged in developing personalized cell-based therapies aimed at treating cancer, specifically through neoantigen-specific adoptive TCR T-cell therapies for solid tumors. The company utilizes advanced bioinformatics to analyze patients' tumor and normal DNA and RNA, identifying neoantigen peptides that provoke targeted T cell responses against cancer cells. By recognizing neo-epitopes, which are unique mutations in each patient's cancer, PACT Pharma creates autologous T cells engineered to specifically target and eliminate tumors expressing these neo-antigens. Founded in 2016 and headquartered in South San Francisco, California, PACT Pharma is focused on innovative approaches to enhance cancer treatment through tailored immunotherapies.

Kin Euphorics is a New York-based company, founded in 2017, that specializes in non-alcoholic beverages designed to enhance social experiences. The company's offerings include ready-to-drink tonics made from a combination of nootropics, adaptogens, and botanicals. These functional beverages aim to promote a sense of focused relaxation, helping consumers unwind without inducing sleepiness or compromising cognitive function. Kin Euphorics targets individuals seeking a balanced and nourishing alternative to traditional alcoholic drinks, allowing them to enjoy social interactions while supporting their mental well-being.

Rallybio, LLC is a biopharmaceutical company based in New Haven, Connecticut, that focuses on developing innovative therapies for patients with severe and rare disorders. Founded in 2018, the company is dedicated to addressing life-threatening conditions, particularly through its lead product candidate, RLYB211, which aims to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT). This rare disease can lead to uncontrolled bleeding in fetuses and newborns. Rallybio's research emphasizes the development of antibody, small molecule, and engineered protein therapies, primarily in the late discovery to early clinical stages. Through its efforts, Rallybio seeks to transform the lives of patients suffering from devastating diseases.

Vineti is a commercial cloud-based platform that expands patient access to life-saving cells and gene therapies. The software solution offers an independent, purpose-built enterprise solution that is essential for enabling the growth and wide distribution of transformative personalized therapeutics, such as CAR-T cell therapies, for the treatment of late-stage cancer. The Vineti Personalized Therapy Management (PTM) ® platform automates patient-centric supply chains for a wide range of advanced therapies, in all phases of clinical development and commercial operations. Veneti aims to solve the key challenges patients, medical providers, pharmaceutical companies, and regulators face in the delivery and commercialization of personalized medicine. Amy DuRoss, Heidi M. Hagen, Malek Faham, Razmik Abnous, and Stephen Ting co-founded Vineti in San Francisco, California in 2016.

Arvinas is a pharmaceutical company that focuses on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Its proprietary approach is the targeting of disease-causing proteins for degradation thus eliminating them from the body. The company was founded in 2013 and is headquartered in Connecticut, United States.

Unchained Labs is a developer of life science biologics tools designed to help researchers break free from tools that just don't cut it. It offers a multiplex protein stability platform for biologics that measures a host of protein stability parameters. The company's products include protein sizing systems, stability quantifiers, benchtop workflow solutions, automated buffer exchanges, concentration liberators, particle identifiers, and more, enabling biologics researchers to speed up their work with ease. Unchained Labs was established in 2013 and is based in Pleasanton, California, USA.

IDEAYA Biosciences is an oncology-focused biotechnology company based in South San Francisco, California, dedicated to the discovery and development of targeted therapeutics for genetically defined patient populations. The company specializes in precision medicine using molecular diagnostics and synthetic lethality approaches to address cancer treatment. Its lead product candidate, IDE196, is a protein kinase C inhibitor currently undergoing Phase 1/2 clinical trials for cancers associated with GNAQ or GNA11 gene mutations. IDEAYA's preclinical pipeline includes programs targeting various mechanisms related to DNA damage and repair, such as MAT2A for tumors with MTAP deletions, Pol-theta for homologous recombination deficiency, and PARG for BRCA2 mutation context. The company collaborates with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase, while also engaging in partnerships for clinical trials with Pfizer and GlaxoSmithKline. Founded in 2015, IDEAYA aims to advance innovative therapies for enhancing immunotherapy responses and improving patient outcomes in oncology.

Liquidia Technologies is a late-stage clinical biopharmaceutical company based in Morrisville, North Carolina, that specializes in the development and commercialization of human therapeutics. The company utilizes its proprietary PRINT technology, a particle engineering platform that allows for the precise production of uniform drug particles, aimed at improving the safety, efficacy, and performance of various therapies. Liquidia is currently advancing two key product candidates: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for addressing local post-operative pain. In addition to its internal pipeline, Liquidia collaborates with leading pharmaceutical companies to leverage its PRINT technology across multiple therapeutic areas and drug types. The company also offers strategy and commercialization services for rare disease pharmaceutical products, including a generic formulation of treprostinil for pulmonary arterial hypertension. Founded in 2004, Liquidia Technologies continues to focus on transforming patient care through innovative therapeutic solutions.

Truveris, Inc. is a health information technology company based in New York that focuses on the management of pharmacy benefits and prescription drug costs. Founded in 2009, the company offers a comprehensive platform that includes solutions such as RxChoice, TruBid, and RxDash, which cater to various stakeholders in the prescription drug ecosystem, including pharmaceutical manufacturers, pharmacy benefit managers, and payers. Truveris leverages data-driven innovations to provide actionable insights that help clients navigate the complexities of pharmacy spending, ensure regulatory compliance, and validate claim payment accuracy. By offering tools for managing the entire pharmacy benefits lifecycle—from request for proposal to bill review—Truveris aims to enhance transparency and efficiency in the prescription drug market. The company's backing from multiple venture capital firms underscores its commitment to addressing rising costs and improving access to prescription medications.

Unchained Labs is a developer of life science biologics tools designed to help researchers break free from tools that just don't cut it. It offers a multiplex protein stability platform for biologics that measures a host of protein stability parameters. The company's products include protein sizing systems, stability quantifiers, benchtop workflow solutions, automated buffer exchanges, concentration liberators, particle identifiers, and more, enabling biologics researchers to speed up their work with ease. Unchained Labs was established in 2013 and is based in Pleasanton, California, USA.

Vivace Therapeutics, Inc. is a small molecule discovery and development company focused on creating innovative cancer therapeutics by targeting the Hippo pathway, which plays a critical role in tissue regeneration and organ development. Founded in 2014, the company is based in San Mateo, California, and operates with a commitment to advancing novel therapies that can improve outcomes for cancer patients. Vivace Therapeutics emphasizes a capital-efficient and modality-indifferent approach, collaborating with leading academic laboratories to leverage cutting-edge research. Its experienced management team and top-tier scientists aim to develop treatments that can be used independently or in combination with existing therapies, ultimately striving to enhance the lives of individuals affected by cancer.

Hyalex Orthopaedics, Inc. is a medical device company based in Lexington, Massachusetts, focused on developing innovative products that utilize HYALEX technology, a synthetic polymer engineered to mimic cartilage. Founded in 2016, the company specializes in creating a biomimetic material that can effectively simulate healthy cartilage to treat diseased or damaged joints. The unique properties of HYALEX allow it to maintain low friction and wear, even under the significant loads typically experienced in human joints. This capability enables surgeons to replace arthritic cartilage while preserving healthy bone. Although Hyalex Orthopaedics is advancing its product development, its offerings have not yet received approval for use in humans from any regulatory agency.

Iterum Therapeutics plc is a clinical-stage pharmaceutical company based in Dublin, Ireland, focused on developing innovative anti-infectives to address the global challenge of multi-drug resistant pathogens. Founded in 2015, the company is advancing sulopenem, a novel penem anti-infective compound available in both oral and intravenous formulations. Currently in Phase III clinical trials, sulopenem aims to treat uncomplicated and complicated urinary tract infections, as well as complicated intra-abdominal infections. The company's goal is to provide effective solutions for serious infections caused by resistant bacteria, thereby improving patient outcomes and addressing the limitations of existing antibiotic treatments.

Onkos Surgical Inc. is a company focused on providing innovative technologies and solutions for surgical oncologists, particularly in the treatment of musculoskeletal cancers and complex conditions. Established in 2014 and headquartered in Parsippany, New Jersey, Onkos Surgical offers products like GenVie, a magnesium bone scaffolding technology, and the ELEOS Proximal Tibia, a 3D-printed limb salvage replacement. The company emphasizes precision orthopedics, leveraging expertise in patient imaging analysis and personalized surgical planning. By addressing the clinical challenges associated with tumor surgery, Onkos Surgical aims to deliver diverse solutions tailored to the needs of patients, including children, who may require specialized care.

Antiva Biosciences is a biopharmaceutical company developing novel, localized therapeutics for the treatment of diseases caused by HPV infection. The company was founded as Hera Therapeutics in 2012 by Dr. Karl Hostetler at The University of California San Diego. They are now Antiva Biosciences which is headquartered in South San Francisco.

Arrakis Therapeutics is a biopharmaceutical company focused on developing innovative drugs that target ribonucleic acid (RNA) to treat a variety of diseases, including cancer and rare genetic disorders. The company employs a unique drug discovery platform that integrates advanced RNA bioinformatics and structural tools, allowing it to identify new RNA targets and create RNA-targeted small molecules (rSMs). Its proprietary pipeline consists of these rSMs aimed at genetically validated targets across multiple disease areas. Additionally, Arrakis offers SHAPEware, a software tool that assists in predicting RNA secondary structures and potential ligand-binding sites. Founded in 2015 and based in Waltham, Massachusetts, Arrakis Therapeutics aims to enhance therapeutic options for patients through its cutting-edge research and development efforts.

Dauntless Pharmaceuticals, Inc. is a biopharmaceutical company based in San Diego, California, focused on developing specialty therapeutic drugs for endocrine cancers. The company offers Dauntless 1, a treatment specifically designed for these cancers, and is also developing DP1038, another therapeutic agent in the same area. Established in 2015, Dauntless Pharmaceuticals aims to provide innovative alternatives to existing treatments, including a non-injectable somatostatin analog, which offers a less invasive option compared to traditional injectable therapies used for conditions like acromegaly and neuroendocrine tumors. The company holds a diverse portfolio of assets at various stages of development, reflecting its commitment to advancing patient care through its therapeutic innovations.

Abyrx, Inc. is a company that develops, manufactures, and distributes therapeutic devices specifically designed for surgical procedures. Founded in 2013 and based in Irvington, New York, Abyrx offers a range of products, including resorbable hemostatic bone putties and applicator devices. These innovative solutions are aimed at addressing bone bleeding and facilitating bone healing by adhering to bleeding surfaces. The company’s technology also enables the delivery of drugs directly to the bone, enhancing recovery processes in various surgical fields, including orthopedic, cranial, maxillofacial, trauma, cardiothoracic, and spine surgeries. Abyrx has expanded its portfolio through acquisitions, including the HEMASORB Resorbable Hemostatic Bone Putty and the rights to develop advanced polymer technology for bone applications.

Annum Health delivers the modern alternative to traditional rehab for heavy drinking. Co-founded by proven leaders in health care, technology and alcohol treatment, Annum transforms the treatment experience while eliminating profound barriers to care — high cost, personal and professional disruption, and stigma. At a fraction of the price of inpatient care at a traditional rehab facility, Annum’s tech-enabled solution fully integrates therapy, coaching, medication and support over the course of up to a year to help people reach their individual goals.

Relievant Medsystems, Inc. is a medical device company focused on addressing chronic axial low back pain through a minimally invasive procedure known as Intracept. This innovative treatment specifically targets the basivertebral nerve, utilizing radio-frequency energy delivered through a small access tube into the vertebral body to ablate the nerve. The procedure is performed under real-time fluoroscopic guidance, ensuring precision and safety. Founded in 2004 and headquartered in Minneapolis, Minnesota, with an additional office in Sunnyvale, California, Relievant aims to provide low-risk therapeutic solutions that significantly improve the quality of life for patients suffering from vertebrogenic low back pain.

Chrono Therapeutics Inc., a digital transdermal drug delivery company, develops SmartStop, a digital nicotine replacement therapy. Its wearable solution tailors the timing and dose sizes of drugs, preempts predictable peak disease, and addiction symptoms with a device. The company was incorporated in 2003 and is based in Hayward, California.

OncoResponse Inc. is an immuno-oncology company based in Houston, Texas, focused on discovering new cancer immunotherapies and therapeutic antibodies. The company collaborates with MD Anderson Cancer Center to utilize the I-STAR™ platform, which analyzes the human memory B-cell repertoire of patients who have demonstrated exceptional responses to immunotherapy, referred to as "Elite Responders." By studying these patients, OncoResponse aims to harness the human immune system to identify fully human monoclonal antibodies and novel targets. This approach is intended to facilitate the development of innovative antibody-derived therapeutics for cancer treatment.

IDEAYA Biosciences is an oncology-focused biotechnology company based in South San Francisco, California, dedicated to the discovery and development of targeted therapeutics for genetically defined patient populations. The company specializes in precision medicine using molecular diagnostics and synthetic lethality approaches to address cancer treatment. Its lead product candidate, IDE196, is a protein kinase C inhibitor currently undergoing Phase 1/2 clinical trials for cancers associated with GNAQ or GNA11 gene mutations. IDEAYA's preclinical pipeline includes programs targeting various mechanisms related to DNA damage and repair, such as MAT2A for tumors with MTAP deletions, Pol-theta for homologous recombination deficiency, and PARG for BRCA2 mutation context. The company collaborates with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase, while also engaging in partnerships for clinical trials with Pfizer and GlaxoSmithKline. Founded in 2015, IDEAYA aims to advance innovative therapies for enhancing immunotherapy responses and improving patient outcomes in oncology.

Iterum Therapeutics plc is a clinical-stage pharmaceutical company based in Dublin, Ireland, focused on developing innovative anti-infectives to address the global challenge of multi-drug resistant pathogens. Founded in 2015, the company is advancing sulopenem, a novel penem anti-infective compound available in both oral and intravenous formulations. Currently in Phase III clinical trials, sulopenem aims to treat uncomplicated and complicated urinary tract infections, as well as complicated intra-abdominal infections. The company's goal is to provide effective solutions for serious infections caused by resistant bacteria, thereby improving patient outcomes and addressing the limitations of existing antibiotic treatments.

Tizona Therapeutics, Inc. is an immunotherapy company focused on developing treatments for cancer and autoimmune diseases. Founded in 2014 and located in South San Francisco, California, the company is known for its innovative products, including an Anti-CCR4 antibody aimed at cancer treatment, as well as IL-35 antagonists and agonists that target immune response modulation. Tizona is actively collaborating with its scientific founders to enhance understanding of the role of regulatory T cells in tumor immunosuppression, which is crucial for developing effective therapies. By targeting specific cell types and biological mechanisms responsible for immune suppression in the tumor microenvironment, Tizona aims to provide patients with durable and complete remissions from their conditions.

Unchained Labs is a developer of life science biologics tools designed to help researchers break free from tools that just don't cut it. It offers a multiplex protein stability platform for biologics that measures a host of protein stability parameters. The company's products include protein sizing systems, stability quantifiers, benchtop workflow solutions, automated buffer exchanges, concentration liberators, particle identifiers, and more, enabling biologics researchers to speed up their work with ease. Unchained Labs was established in 2013 and is based in Pleasanton, California, USA.

NextCure, Inc. is a clinical-stage biopharmaceutical company based in Beltsville, Maryland, dedicated to discovering and developing innovative immunomedicines for cancer and other immune-related diseases. The company’s lead product candidate, NC318, is currently undergoing Phase 2 clinical trials aimed at treating advanced or metastatic solid tumors. Additionally, NextCure is advancing NC410, an immunomedicine designed to counteract immune suppression through targeting an immune modulator known as Leukocyte-Associated Immunoglobulin-like Receptor 1. The company is also engaged in research programs evaluating novel immunomodulatory molecules, including antibodies in preclinical development that target specific immune modulators in inflamed tissues and tumor microenvironments. NextCure has established a license agreement with Yale University and collaborates with Eli Lilly and Company for research and development efforts. Founded in 2015, the company leverages proprietary platforms to identify biologically relevant targets and develop first-in-class immunotherapy products.

EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company is known for its Transoral Incisionless Fundoplication (TIF®) procedure, which provides a minimally invasive alternative to traditional surgical methods by allowing treatment without external incisions. Key products include the EsophyX technology, which facilitates transoral reconstructive surgery, and the SerosaFuse Fasteners, designed for secure tissue attachment. Additionally, EndoGastric Solutions offers training courses for surgeons and a range of consultative support services. Founded in 2002 and headquartered in Redmond, Washington, the company also has an office in San Mateo, California.

Arvinas is a pharmaceutical company that focuses on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Its proprietary approach is the targeting of disease-causing proteins for degradation thus eliminating them from the body. The company was founded in 2013 and is headquartered in Connecticut, United States.

Antiva Biosciences is a biopharmaceutical company developing novel, localized therapeutics for the treatment of diseases caused by HPV infection. The company was founded as Hera Therapeutics in 2012 by Dr. Karl Hostetler at The University of California San Diego. They are now Antiva Biosciences which is headquartered in South San Francisco.

Protagonist Pty Ltd is a biotechnology company based in Brisbane, Australia, focused on developing innovative therapeutics for inflammatory and metabolic conditions. The company specializes in discovering peptide and small molecule compounds that mimic or inhibit protein-protein interactions relevant to therapeutic applications. Protagonist Pty Ltd also aims to identify drug candidates for targets that have traditionally been resistant to small molecule discovery, creating arrays of molecules that explore biologically-relevant chemical diversity. Originally founded as Cytokine Mimetics Pty Ltd in 2001, it operates as a subsidiary of Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops peptide-based products to address unmet medical needs, particularly in hematology and gastroenterology. Protagonist Therapeutics has a portfolio that includes drug candidates in various stages of clinical trials for conditions such as beta-thalassemia and inflammatory bowel disease.

Spyryx Biosciences is a biopharmaceutical company based in Durham, North Carolina, specializing in the development of inhaled peptide therapeutics aimed at treating obstructive lung diseases, specifically cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). Founded in 2013 by Dr. Robert Tarran, the company emerged from his discovery of a novel mechanism by which the lungs regulate surface fluid. This mechanism is impaired in CF patients due to genetic mutations, leading to dehydration, mucus buildup, and subsequent lung damage. Spyryx's therapeutic approach targets this underlying dysfunction, showing promising results in preclinical studies by significantly improving survival in animal models of CF. Importantly, the treatment is designed to function independently of the specific genetic mutations responsible for CF, offering potential benefits to a broader patient population. Additionally, the company is exploring the relevance of this fluid regulation mechanism in COPD, a condition characterized by chronic bronchitis and emphysema, as part of its commitment to addressing multiple obstructive lung diseases.

Unchained Labs is a developer of life science biologics tools designed to help researchers break free from tools that just don't cut it. It offers a multiplex protein stability platform for biologics that measures a host of protein stability parameters. The company's products include protein sizing systems, stability quantifiers, benchtop workflow solutions, automated buffer exchanges, concentration liberators, particle identifiers, and more, enabling biologics researchers to speed up their work with ease. Unchained Labs was established in 2013 and is based in Pleasanton, California, USA.

CytomX Therapeutics is an early stage, privately-funded biotechnology company developing Probodiesâ„¢, proteolytically-activated antibodies. Probodies, by their ability to site-direct the activity of antibodies, will result in an improved therapeutic index for validated targets as well enable the drugging of targets with broad tissue expression. Their mission, alone and with the help of partners, is to provide patients with more effective and less toxic therapies for severe illnesses such as cancer and inflammatory diseases.

Vivace Therapeutics, Inc. is a small molecule discovery and development company focused on creating innovative cancer therapeutics by targeting the Hippo pathway, which plays a critical role in tissue regeneration and organ development. Founded in 2014, the company is based in San Mateo, California, and operates with a commitment to advancing novel therapies that can improve outcomes for cancer patients. Vivace Therapeutics emphasizes a capital-efficient and modality-indifferent approach, collaborating with leading academic laboratories to leverage cutting-edge research. Its experienced management team and top-tier scientists aim to develop treatments that can be used independently or in combination with existing therapies, ultimately striving to enhance the lives of individuals affected by cancer.

LQ3 Pharmaceuticals, Inc. is a healthcare company based in Morrisville, North Carolina, that was incorporated in 2013. The company specializes in the pharmaceutical sector, developing and providing innovative healthcare solutions. Its focus is on improving patient outcomes through research and development of effective medications.

ALDEA Pharmaceuticals, Inc. is focused on developing small-molecule modulators of the aldehyde dehydrogenase (ALDH) enzyme superfamily to address toxic aldehyde-related diseases. The company's proprietary technology aims to create new therapeutic options for a range of conditions, including acute alcohol toxicity and rare diseases such as Fanconi anemia. One of its key compounds is an ALDH activator that enhances the detoxification of acetaldehyde, which can help alleviate acute symptoms and reduce long-term tissue damage and cancer risk associated with alcohol metabolism. Founded in 2008 and based in Redwood City, California, ALDEA Pharmaceuticals is committed to advancing treatments that target significant unmet medical needs.

Civitas Therapeutics is a biopharmaceutical company dedicated to developing therapies for pulmonary delivery. The company focuses on creating innovative treatments for central nervous system and respiratory disorders, with a particular emphasis on conditions such as multiple sclerosis and spinal cord injuries. Civitas Therapeutics aims to improve the health and quality of life for patients across the United States through its specialized drug delivery systems.

Dermira is a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients. Dermira’s portfolio of five product candidates targets significant market opportunities. It was founded in 2010 and headquartered in Menlo Park, California.

Truveris, Inc. is a health information technology company based in New York that focuses on the management of pharmacy benefits and prescription drug costs. Founded in 2009, the company offers a comprehensive platform that includes solutions such as RxChoice, TruBid, and RxDash, which cater to various stakeholders in the prescription drug ecosystem, including pharmaceutical manufacturers, pharmacy benefit managers, and payers. Truveris leverages data-driven innovations to provide actionable insights that help clients navigate the complexities of pharmacy spending, ensure regulatory compliance, and validate claim payment accuracy. By offering tools for managing the entire pharmacy benefits lifecycle—from request for proposal to bill review—Truveris aims to enhance transparency and efficiency in the prescription drug market. The company's backing from multiple venture capital firms underscores its commitment to addressing rising costs and improving access to prescription medications.

Chrono Therapeutics Inc., a digital transdermal drug delivery company, develops SmartStop, a digital nicotine replacement therapy. Its wearable solution tailors the timing and dose sizes of drugs, preempts predictable peak disease, and addiction symptoms with a device. The company was incorporated in 2003 and is based in Hayward, California.

EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company is known for its Transoral Incisionless Fundoplication (TIF®) procedure, which provides a minimally invasive alternative to traditional surgical methods by allowing treatment without external incisions. Key products include the EsophyX technology, which facilitates transoral reconstructive surgery, and the SerosaFuse Fasteners, designed for secure tissue attachment. Additionally, EndoGastric Solutions offers training courses for surgeons and a range of consultative support services. Founded in 2002 and headquartered in Redmond, Washington, the company also has an office in San Mateo, California.

Transcend Medical, Inc. is an ophthalmic device company dedicated to developing medical devices for the treatment of glaucoma, a leading cause of irreversible blindness in adults. Founded in 2005 and based in Menlo Park, California, the company emerged from ForSight Labs and focuses on minimally invasive solutions to replace traditional invasive therapies. Its flagship product, the CyPass Micro-Stent, is designed to be inserted during routine cataract surgery to help reduce intraocular pressure. Transcend Medical also offers the Vold Gonio Lens for use in micro-invasive glaucoma surgery and provides clinical trial services. The CyPass Micro-Stent received CE mark approval in 2008 and has been evaluated in various clinical studies, including the COMPASS multi-center trial. The company operates as a subsidiary of Alcon Holdings, Inc.

Envisia Therapeutics Inc. is a biotechnology company dedicated to discovering and developing innovative therapies for ocular conditions. Founded in 2013 and based in Durham, North Carolina, the company addresses significant unmet medical needs in ophthalmology, particularly for conditions like glaucoma. Envisia's lead product, ENV515, is a prostaglandin analogue formulated with a biodegradable PRINT particle technology, designed to provide sustained intraocular pressure reduction over several months. The company's research and development efforts focus on overcoming barriers associated with traditional ocular therapies, such as poor drug uptake and systemic side effects, by utilizing biocompatible polymers and extended-release delivery systems. With an increasing demand for effective ocular therapeutics due to a rapidly aging population, Envisia aims to significantly improve patient outcomes and adherence to treatment protocols in the field of eye care.

Arvinas is a pharmaceutical company that focuses on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Its proprietary approach is the targeting of disease-causing proteins for degradation thus eliminating them from the body. The company was founded in 2013 and is headquartered in Connecticut, United States.

Civitas Therapeutics is a biopharmaceutical company dedicated to developing therapies for pulmonary delivery. The company focuses on creating innovative treatments for central nervous system and respiratory disorders, with a particular emphasis on conditions such as multiple sclerosis and spinal cord injuries. Civitas Therapeutics aims to improve the health and quality of life for patients across the United States through its specialized drug delivery systems.

Semnur Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to the development of innovative non-opioid medications aimed at treating lumbar radicular pain. The company focuses on creating products that address the needs of pain management practitioners and their patients, particularly those suffering from back pain. By prioritizing clinical and commercial development, Semnur aims to enhance the efficacy and safety of pain management therapies, ultimately improving treatment outcomes for underserved patient populations.

Dermira is a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients. Dermira’s portfolio of five product candidates targets significant market opportunities. It was founded in 2010 and headquartered in Menlo Park, California.

AtheroMed, Inc. develops treatments for peripheral arterial disease. The company was incorporated in 2006 and is headquartered in Menlo Park, California.

ALDEA Pharmaceuticals, Inc. is focused on developing small-molecule modulators of the aldehyde dehydrogenase (ALDH) enzyme superfamily to address toxic aldehyde-related diseases. The company's proprietary technology aims to create new therapeutic options for a range of conditions, including acute alcohol toxicity and rare diseases such as Fanconi anemia. One of its key compounds is an ALDH activator that enhances the detoxification of acetaldehyde, which can help alleviate acute symptoms and reduce long-term tissue damage and cancer risk associated with alcohol metabolism. Founded in 2008 and based in Redwood City, California, ALDEA Pharmaceuticals is committed to advancing treatments that target significant unmet medical needs.

Theraclone Sciences, Inc. is a Seattle-based discovery-stage biotechnology company focused on developing novel therapeutic antibodies for the treatment of cancer and infectious diseases. The company utilizes its In-Situ Therapeutic Antibody Rescue technology to rapidly test human antibodies, identifying those with exceptional biological functions. Notable among its offerings is TCN-032, a recombinant human monoclonal antibody aimed at treating patients hospitalized with severe influenza. Theraclone’s antibody programs are in varying stages of preclinical and clinical development, targeting significant unmet medical needs such as triple negative and endocrine treatment-resistant HER-2 negative breast cancer, infectious disease-associated cancers, and multidrug-resistant bacteria. Theraclone was founded in 2004 and was formerly known as Spaltudaq Corporation, changing its name in March 2009. The company is privately held and has received venture funding from several investment firms.

Novira Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops antiviral drugs for the treatment of chronic hepatitis B infection. It develops core and cccDNA inhibitor anti-HBV drugs. Novira Therapeutics, Inc. was formerly known as Molecmo Nanobiotechnologies, Inc. The company was incorporated in 2006 and is based in Doylestown, Pennsylvania. As of December 4, 2015, Novira Therapeutics, Inc. operates as a subsidiary of Johnson & Johnson.

Marinus Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of ganaxolone, offering a new mechanism of action with safe and convenient dosing, for adult and pediatric patient populations in acute and chronic care settings. The company was founded in 2003 and is based in Branford, Connecticut.

Labrys Biologics Inc., a company focused on treatments for chronic migraine. Labrys Biologics has acquired worldwide rights to RN-307 from Pfizer Inc. RN-307 is an antibody for the treatment of chronic migraine.

Labrys Biologics Inc., a company focused on treatments for chronic migraine. Labrys Biologics has acquired worldwide rights to RN-307 from Pfizer Inc. RN-307 is an antibody for the treatment of chronic migraine.

CytomX Therapeutics is an early stage, privately-funded biotechnology company developing Probodiesâ„¢, proteolytically-activated antibodies. Probodies, by their ability to site-direct the activity of antibodies, will result in an improved therapeutic index for validated targets as well enable the drugging of targets with broad tissue expression. Their mission, alone and with the help of partners, is to provide patients with more effective and less toxic therapies for severe illnesses such as cancer and inflammatory diseases.

Arstasis is a medical device manufacturer dedicated to bringing innovative access devices to cardiologists, interventional radiologists, their staff, and patients. The device is used in the Arstaotomyâ„¢ procedure, a new way to gain access to the femoral artery that some physicians believe results in a more pleasant and efficient cath lab and post-procedure experience for clinician and patient alike. It was founded in 2006 and headquartered in Redwood City, California.

EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company is known for its Transoral Incisionless Fundoplication (TIF®) procedure, which provides a minimally invasive alternative to traditional surgical methods by allowing treatment without external incisions. Key products include the EsophyX technology, which facilitates transoral reconstructive surgery, and the SerosaFuse Fasteners, designed for secure tissue attachment. Additionally, EndoGastric Solutions offers training courses for surgeons and a range of consultative support services. Founded in 2002 and headquartered in Redmond, Washington, the company also has an office in San Mateo, California.

ALDEA Pharmaceuticals, Inc. is focused on developing small-molecule modulators of the aldehyde dehydrogenase (ALDH) enzyme superfamily to address toxic aldehyde-related diseases. The company's proprietary technology aims to create new therapeutic options for a range of conditions, including acute alcohol toxicity and rare diseases such as Fanconi anemia. One of its key compounds is an ALDH activator that enhances the detoxification of acetaldehyde, which can help alleviate acute symptoms and reduce long-term tissue damage and cancer risk associated with alcohol metabolism. Founded in 2008 and based in Redwood City, California, ALDEA Pharmaceuticals is committed to advancing treatments that target significant unmet medical needs.

EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company is known for its Transoral Incisionless Fundoplication (TIF®) procedure, which provides a minimally invasive alternative to traditional surgical methods by allowing treatment without external incisions. Key products include the EsophyX technology, which facilitates transoral reconstructive surgery, and the SerosaFuse Fasteners, designed for secure tissue attachment. Additionally, EndoGastric Solutions offers training courses for surgeons and a range of consultative support services. Founded in 2002 and headquartered in Redmond, Washington, the company also has an office in San Mateo, California.

Relievant Medsystems, Inc. is a medical device company focused on addressing chronic axial low back pain through a minimally invasive procedure known as Intracept. This innovative treatment specifically targets the basivertebral nerve, utilizing radio-frequency energy delivered through a small access tube into the vertebral body to ablate the nerve. The procedure is performed under real-time fluoroscopic guidance, ensuring precision and safety. Founded in 2004 and headquartered in Minneapolis, Minnesota, with an additional office in Sunnyvale, California, Relievant aims to provide low-risk therapeutic solutions that significantly improve the quality of life for patients suffering from vertebrogenic low back pain.

EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company is known for its Transoral Incisionless Fundoplication (TIF®) procedure, which provides a minimally invasive alternative to traditional surgical methods by allowing treatment without external incisions. Key products include the EsophyX technology, which facilitates transoral reconstructive surgery, and the SerosaFuse Fasteners, designed for secure tissue attachment. Additionally, EndoGastric Solutions offers training courses for surgeons and a range of consultative support services. Founded in 2002 and headquartered in Redmond, Washington, the company also has an office in San Mateo, California.

AtheroMed, Inc. develops treatments for peripheral arterial disease. The company was incorporated in 2006 and is headquartered in Menlo Park, California.

Altheos, Inc. is an early stage biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs. Altheos, Inc. completed $20MM series A financing in March 2010 led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital. The financing will be used primarily for the development of ATS907, a selective Rho-kinase inhibitor for topical treatment of glaucoma that Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of highly active compounds specifically for topical treatment for glaucoma.

Transcend Medical, Inc. is an ophthalmic device company dedicated to developing medical devices for the treatment of glaucoma, a leading cause of irreversible blindness in adults. Founded in 2005 and based in Menlo Park, California, the company emerged from ForSight Labs and focuses on minimally invasive solutions to replace traditional invasive therapies. Its flagship product, the CyPass Micro-Stent, is designed to be inserted during routine cataract surgery to help reduce intraocular pressure. Transcend Medical also offers the Vold Gonio Lens for use in micro-invasive glaucoma surgery and provides clinical trial services. The CyPass Micro-Stent received CE mark approval in 2008 and has been evaluated in various clinical studies, including the COMPASS multi-center trial. The company operates as a subsidiary of Alcon Holdings, Inc.

Founded in 2008, Elevation Pharmaceuticals is developing a pipeline of improved aerosol drug products for COPD patients. There founding team has a successful track record starting companies and building dedicated teams to develop new drug products that improve patients' lives. At Elevation, they have a disciplined approach to strategic decision-making that helps us stay focused on the path with the highest probability of success. They are executing our drug development plans with passion, integrity, and a high sense of urgency in order to meet the needs and expectations of our stakeholders -- employees, investors, partners, and patients.

Kalidex Pharmaceuticals, Inc. manufactures pharmaceuticals. The company was incorporated in 2010 and is based in Menlo Park, California.

Theraclone Sciences, Inc. is a Seattle-based discovery-stage biotechnology company focused on developing novel therapeutic antibodies for the treatment of cancer and infectious diseases. The company utilizes its In-Situ Therapeutic Antibody Rescue technology to rapidly test human antibodies, identifying those with exceptional biological functions. Notable among its offerings is TCN-032, a recombinant human monoclonal antibody aimed at treating patients hospitalized with severe influenza. Theraclone’s antibody programs are in varying stages of preclinical and clinical development, targeting significant unmet medical needs such as triple negative and endocrine treatment-resistant HER-2 negative breast cancer, infectious disease-associated cancers, and multidrug-resistant bacteria. Theraclone was founded in 2004 and was formerly known as Spaltudaq Corporation, changing its name in March 2009. The company is privately held and has received venture funding from several investment firms.

Dermira is a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients. Dermira’s portfolio of five product candidates targets significant market opportunities. It was founded in 2010 and headquartered in Menlo Park, California.